MacroGenics Beheer
Beheer criteriumcontroles 2/4
De CEO MacroGenics is Eric Risser, benoemd in Aug2025, heeft een ambtstermijn van minder dan een jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.08M, bestaande uit 27% salaris en 73% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.12% van de aandelen van het bedrijf, ter waarde $ 232.28K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.5 jaar en 8.5 jaar.
Belangrijke informatie
Eric Risser
Algemeen directeur
US$2.1m
Totale compensatie
| Percentage CEO-salaris | 27.01% |
| Dienstverband CEO | less than a year |
| Eigendom CEO | 0.1% |
| Management gemiddelde ambtstermijn | 2.5yrs |
| Gemiddelde ambtstermijn bestuur | 8.5yrs |
Recente managementupdates
Recent updates
Analyse-update • Apr 26
MGNX: Antibody Drug Conjugate Pipeline And 2026 Data Will Drive Repricing
Narrative Update on MacroGenics Analysts have raised their price targets on MacroGenics by $2 to $4. They cite updated revenue assumptions and interest in the company’s antibody drug conjugate pipeline as key factors behind the change.Analyse-update • Apr 12
MGNX: Antibody Drug Conjugate Pipeline And Tubulus Deal Will Drive Repricing
Analysts raised their price target for MacroGenics from $5.00 to $9.00, citing updated assumptions for potential revenue growth, slightly higher profit margins, a lower discount rate and recent positive sentiment following the Tubulus deal and the outlook for antibody-drug conjugate data. Analyst Commentary Bullish analysts are pointing to recent research updates as a sign that expectations for MacroGenics are shifting toward a more constructive view, with price targets and ratings adjusted to reflect changing assumptions around future execution and potential revenue streams.Seeking Alpha • Apr 10
MacroGenics: Oncology Opportunities In Play, But Investing Feels Like A Gamble
Summary MacroGenics (MGNX) is rated Hold, reflecting significant upside potential but high risk and a limited funding runway beyond 2027. MGNX’s pipeline includes antibody drug conjugates and lorigerlimab, with the latter’s Phase 2 clinical hold recently lifted by the FDA. Key 2026 catalysts include clinical data from MGC026, MGC028, and the LINNET study, plus an IND submission for MGC030. Despite past setbacks and a $190m cash position, MGNX’s current valuation implies little pipeline value, making study success critical for future funding. Read the full article on Seeking AlphaAnalyse-artikel • Jan 06
There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues Despite A 26% Share Price Rise
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders are no doubt pleased to see that the share price has bounced 26% in the...
Analyse-update • Sep 25
LORIKEET And LINNET Trials Will Spur Advances Amid Liquidity Risks
The consensus analyst price target for MacroGenics increased to $3.75, primarily reflecting a higher expected future P/E multiple despite a decline in net profit margin. What's in the News Eric Risser appointed Chief Executive Officer, succeeding long-time CEO Scott Koenig; Risser has extensive company and industry experience, having led corporate development efforts that generated $1.6 billion in non-dilutive capital.Analyse-artikel • Sep 08
MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 30% But Its Business Prospects Need A Lift Too
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders would be excited to see that the share price has had a great month...Analyse-update • Aug 16
LORIKEET And LINNET Trials Will Spur Advances Amid Liquidity Risks
Despite an improving net profit margin and a sharply lower future P/E multiple reflecting more attractive valuation, the consensus analyst price target for MacroGenics has been notably reduced from $4.20 to $3.40. What's in the News Eric Risser appointed CEO, succeeding longtime leader Scott Koenig; Risser brings significant operational and business development experience, including generating over $1.6 billion in non-dilutive capital for the company.Analyse-artikel • Jul 24
MacroGenics, Inc. (NASDAQ:MGNX) Surges 37% Yet Its Low P/S Is No Reason For Excitement
MacroGenics, Inc. ( NASDAQ:MGNX ) shares have had a really impressive month, gaining 37% after a shaky period...Analyse-artikel • May 21
Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders will have a reason to smile today, with the analysts making substantial...Analyse-artikel • Apr 14
MacroGenics, Inc. (NASDAQ:MGNX) Looks Inexpensive After Falling 42% But Perhaps Not Attractive Enough
Unfortunately for some shareholders, the MacroGenics, Inc. ( NASDAQ:MGNX ) share price has dived 42% in the last thirty...
Nieuwe analyse • Apr 02
LORIKEET And LINNET Trials Will Spur Advances Amid Liquidity Risks
Future revenue growth potential hinges on successful trial outcomes and product approvals in ongoing and upcoming clinical studies.Analyse-artikel • Feb 28
MacroGenics, Inc. (NASDAQ:MGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%
Unfortunately for some shareholders, the MacroGenics, Inc. ( NASDAQ:MGNX ) share price has dived 26% in the last thirty...Seeking Alpha • Feb 27
MacroGenics: Stacking Up A Lot Of Headwinds... But It's Fallen Too Far
Summary MacroGenics' valuation has declined due to continued bad news in 2024, impacting market sentiment. MGNX holds $179.6M in cash and equivalents, with a sustainable cash burn rate for up to 5 years. Sale of the margetuximab franchise poises the company for further financial stability. Operating expenses are expected to rise as clinical programs advance, with management projecting a cash runway into 2026. I think this is a conservative estimate. Although a lot has changed, I think these price levels are attractive for a tentative investment based on catalysts I anticipate in 2025 and beyond. Read the full article on Seeking AlphaSeeking Alpha • Dec 05
MacroGenics: A Productive Biotech With Growing Potential - Still Not A Buy
Summary MacroGenix was previously rated as a "Hold" due to uncertain revenue streams and high annual expenses of ~$300 million. Since the initial rating, MacroGenix's stock has dropped approximately 33%, reflecting ongoing financial challenges. The company's reliance on episodic milestones and minimal product revenues makes it unattractive for new investors. Existing investors might accept the risk, but the current financial outlook remains unattractive for prospective buyers. Read the full article on Seeking AlphaAnalyse-artikel • Aug 01
Party Time: Brokers Just Made Major Increases To Their MacroGenics, Inc. (NASDAQ:MGNX) Earnings Forecasts
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders will have a reason to smile today, with the analysts making substantial...Analyse-artikel • Jul 30
MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders are no doubt pleased to see that the share price has bounced 29% in the...Analyse-artikel • Jul 12
We're A Little Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analyse-artikel • May 13
MacroGenics, Inc.'s (NASDAQ:MGNX) 81% Dip In Price Shows Sentiment Is Matching Revenues
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders that were waiting for something to happen have been dealt a blow with a...Seeking Alpha • May 13
MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)
Summary Macrogenics' stock valuation has dropped over 70% after its first quarter update, creating a new opportunity for investors. The spotlight is on their product vobramitamab duocarmazine, and the phase 2 TAMARACK trial. Macrogenics has between 4 and 5 quarters of cash and investments on hand. Read the full article on Seeking AlphaSeeking Alpha • Apr 05
MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024
Summary Positive safety update released from phase 2 TAMARACK study, using vobra duo for the treatment of patients with metastatic castration-resistant prostate cancer. Updates to interim data from the phase 2 TAMARACK study expected by May 31st of 2024. Radiographic progression-free survival data from the phase 2 TAMARACK study, expected by fall of 2024. The global prostate cancer market size is estimated to reach $27.51 billion by 2032. Read the full article on Seeking AlphaAnalyse-artikel • Feb 28
MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Despite an already strong run, MacroGenics, Inc. ( NASDAQ:MGNX ) shares have been powering on, with a gain of 27% in...Seeking Alpha • Feb 15
MacroGenics: Trying To Build A Better Everything
Summary MacroGenics, Inc. has a pipeline of promising drugs including Vobramitamab Duocarmazine, Lorigerlimab, Tebotelimab, MGD024, and IMGC936. The company has a strong financial position as of their latest report. MacroGenics faces both strengths and risks in their drug development and commercialization efforts. Read the full article on Seeking AlphaAnalyse-artikel • Jan 09
There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues
With a price-to-sales (or "P/S") ratio of 5.4x MacroGenics, Inc. ( NASDAQ:MGNX ) may be sending very bullish signals at...Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Dec 31 2025 | US$2m | US$562k | -US$75m |
| Sep 30 2025 | n/a | n/a | -US$76m |
| Jun 30 2025 | n/a | n/a | -US$36m |
| Mar 31 2025 | n/a | n/a | -US$56m |
| Dec 31 2024 | n/a | n/a | -US$67m |
| Sep 30 2024 | n/a | n/a | -US$98m |
| Jun 30 2024 | n/a | n/a | -US$136m |
| Mar 31 2024 | n/a | n/a | -US$23m |
| Dec 31 2023 | n/a | n/a | -US$9m |
| Sep 30 2023 | n/a | n/a | US$50m |
| Jun 30 2023 | n/a | n/a | US$7m |
| Mar 31 2023 | n/a | n/a | -US$91m |
| Dec 31 2022 | US$2m | US$461k | -US$120m |
| Sep 30 2022 | n/a | n/a | -US$191m |
| Jun 30 2022 | n/a | n/a | -US$219m |
| Mar 31 2022 | n/a | n/a | -US$217m |
| Dec 31 2021 | US$2m | US$428k | -US$202m |
| Sep 30 2021 | n/a | n/a | -US$146m |
| Jun 30 2021 | n/a | n/a | -US$129m |
| Mar 31 2021 | n/a | n/a | -US$136m |
| Dec 31 2020 | US$1m | US$431k | -US$130m |
| Sep 30 2020 | n/a | n/a | -US$158m |
| Jun 30 2020 | n/a | n/a | -US$167m |
| Mar 31 2020 | n/a | n/a | -US$152m |
| Dec 31 2019 | US$2m | US$388k | -US$152m |
Compensatie versus markt: De totale vergoeding ($USD 2.08M ) Eric } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.59M ).
Compensatie versus inkomsten: De vergoeding van Eric is gestegen terwijl het bedrijf verliesgevend is.
CEO
Eric Risser (52 yo)
less than a year
Tenure
US$2,078,854
Compensatie
Mr. Eric Blasius Risser is President, Chief Executive Officer and Director at MacroGenics, Inc. since August 13, 2025. He served as Chief Operating Officer at MacroGenics, Inc. since February 22, 2022 unti...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$2.08m | 0.12% $ 232.3k | |
| Senior VP | 18yrs | US$1.15m | 0.32% $ 620.2k | |
| Senior VP of Research & Chief Scientific Officer | 9.7yrs | US$1.22m | 0.23% $ 438.9k | |
| Senior Vice President of Technical Operations | 3.5yrs | US$1.88m | 0.061% $ 116.0k | |
| Senior VP | 8.9yrs | geen gegevens | 0.049% $ 93.6k | |
| Senior Vice President of Human Resources | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Business Development & Portfolio Planning | less than a year | geen gegevens | geen gegevens | |
| Vice President & Interim Head of Clinical Development | less than a year | geen gegevens | geen gegevens | |
| VP, Controller & Treasurer | 1.5yrs | geen gegevens | 0.020% $ 38.5k |
2.5yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van MGNX wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.5 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$2.08m | 0.12% $ 232.3k | |
| Independent Director | 12.7yrs | US$95.86k | 0.017% $ 33.1k | |
| Independent Director | 5.3yrs | US$110.48k | 0.017% $ 33.1k | |
| Independent Director | 21.6yrs | US$85.86k | 0.069% $ 132.7k | |
| Independent Director | 3.3yrs | US$85.86k | 0.017% $ 33.1k | |
| Director | 24.7yrs | US$969.84k | 1.36% $ 2.6m | |
| Independent Chairman of the Board | 4yrs | US$145.03k | 0.17% $ 334.1k | |
| Independent Director | 3.3yrs | US$80.22k | 0.017% $ 33.1k | |
| Independent Director | 9.3yrs | US$81.91k | 0.017% $ 33.1k | |
| Independent Director | 8.5yrs | US$106.28k | 0.017% $ 33.1k | |
| Independent Director | 9.3yrs | US$85.86k | 0.017% $ 33.1k |
8.5yrs
Gemiddelde duur
67yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van MGNX wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.5 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/07 02:49 |
| Aandelenkoers aan het einde van de dag | 2026/05/07 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
MacroGenics, Inc. wordt gevolgd door 18 analisten. 6 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Peter Lawson | Barclays |
| Etzer Darout | Barclays |
| Stephen V. Byrne | BofA Global Research |